Журнал Сердечная Недостаточность 2015 год Диагностическая и прогностическая ценность новых биомаркеров повреждения почек у больных острой и хронической сердечной недостаточностью


Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
2015/№1

Диагностическая и прогностическая ценность новых биомаркеров повреждения почек у больных острой и хронической сердечной недостаточностью

Кузьмин О. Б., Белянин В. В., Жежа В. В., Сердюк С. В.
ГБОУ ВПО "ОрГМА" МЗ РФ, 460000, Оренбург, ул. Советская, д. 6

Ключевые слова: биомаркеры повреждения почек, острая сердечная недостаточность, ХСН

DOI: 10.18087/rhfj.2015.1.2032

В обзоре представлены результаты клинических исследований, посвященных выяснению диагностической и прогностической ценности биомаркеров повреждения почек: цистатина С, NGAL (липокалин, ассоциированный с нейтральной желатиназой) и KIM-1 (молекула повреждения почки-1) у больных острой СН (ОСН) и ХСН.
  1. Ronco C, McCullough P, Anker CD et al. Cardio-renal syndromes: report from consensus conference of acute dialysis quality initiative. Eur Heart J. 2010 Mar;31 (6):703–11.
  2. Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev. 2012 Mar;17 (2):251–61.
  3. Metha RL, Kellum JA, Shan SV et al. Acute Kidney Injury Network: report of initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11 (2):R31.
  4. Roy AK, Mc Gorrian C, Treacy C et al. A comparison of traditional and novel definition (RIFLE, AKIN, and KDIGO) of acute kidney injury for the prediction of outcomes in acute decompensated heart failure. Cardiorenal Med. 2013 Apr;3 (1):26–37.
  5. Lassus JP, Nieminen MS, Penhkurinen K et al. Markers of renal function and acute renal injury in acute heart failure: definitions and impact on outcomes of cardiorenal syndrome. Eur Heart J. 2010 Nov;31 (22):2791–8.
  6. Perez-Calvo JI, Ruiz-Ruiz FJ, Carrasco-Sanchez FJ et al. Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure. Eur J Intern Med. 2012 Oct;23 (7):599–603.
  7. Lassus JP, Harjola VP, Sund R et al. Prognostic value of cystatin C in acute heart failure in relation to their markers of renal function and NT-proBNP. Eur Heart J. 2007 Aug;28 (15):1841–7.
  8. Dupont M, Wu Y, Hasen SL, Tang WH. Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events. Circ Heart Fail. 2012 Sep 1;5 (5):602–9.
  9. Zamora E, Lupon J, de Antonio M et al. Limited value of cystatin-C over estimated glomerular filtration rate for heart failure risk stratification. PLoS One. 2012;7 (12):e51234.
  10. McCullough PA, Shaw AD, Haase M et al. Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative consensus conference. Contrib Nephrol. 2013;182:13–29.
  11. Schmidt-Ott KM, Mori K, Li JY et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007 Feb;18 (2):407–13.
  12. Breidthardt T, Socrates T, Drexler B et al. Plasma neutrophil gelatinase-associated lipocalin for the prediction of acute kidney injury in acute heart failure. Crit Care. 2012 Jan 7;16 (1):R2.
  13. Mortara A, Bonadies M, Mazzetti S et al. Neutrophil gelatinase-associated lipocalin predict worsening renal function in acute heart failure: methodological and clinical issues. J Cardiovasc Med. 2013 Sep;14 (9):629–34.
  14. Ronco C, Cruz D, Noland BW. Neutrophil gelatinase-associated lipocalin curve and neutrophil gelatinase-associated lipocalin extended range assay: a new biomarker approach in the early diagnosis of acute kidney injury and cardiorenal syndrome. Semin Nephrol. 2012 Jan;32 (1):121–8.
  15. Collins SP, Hart KW, Lindsell CJ et al. Elevated urinary neutrophil gelatinase-associated lipocalin after acute heart failure treatment is associated with worsening renal function and adverse events. Eur J Heart Fail. 2012 Sep;14 (9):1020–9.
  16. Cowie MR, Komajda M, Murray-Thomas T et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results from the prospective outcomes study in heart failure (POSH). Eur Heart J. 2006 May;27 (10):1216–22.
  17. Клименко А. С., Виллевальде С. В., Кобалава Ж. Д. Клинические варианты острого почечного повреждения при декомпенсации хронической сердечной недостаточности: распространенность, тяжесть и исходы. Клиническая нефрология. 2013;5:19–26.
  18. Macdonald S, Arendts J, Nagree Y, Xu XF. Neutrophil gelatinase-associated lipocalin (NGAL) predicts renal injury in acute decompensated cardiac failure: a prospective observational study. BMC Cardiovasc Disord. 2012 Feb 17;12:8.
  19. Aghel A, Shrestha K, Mullens W et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010 Jan;16 (1):49–54.
  20. Maisel AS, Mueller C, Fitzgerald R et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail. 2011 Aug;13 (8):846–51.
  21. Shrestha K, Shao Z, Singh D et al. Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol. 2012 Nov 1;110 (9):1329–35.
  22. Nymo SH, Ueland T, Askevold ET et al. The association between neutrophil gelatinase-associated lipocalin and clinical outcomes in chronic heart failure: results from CORONA. J Intern Med. 2012 May;271 (5):436–43.
  23. Damman K, van Veldhuisen DJ, Navis G et al. Urinary between neutrophil gelatinase-associated lipocalin (NGAL), a marker tubular damage, is increased in patients with chronic heart failure. Eur J Heart Fail. 2008 Oct;10 (10):997–1000.
  24. Lim AI, Tanq SC, Lai KN, Leung JC. Kidney injury molecule-1: more than just an injury marker of the epithelial cells? J Cell Physiol. 2013 May;228 (5):917–24.
  25. de Geus HR, Fortrie G, Betjes MG et al. Time of urinary affects urinary biomarker predictive value for acute kidney injury in critically ill non-septic patients. BMC Nephrol. 2013 Dec 9;14:273.
  26. Liangos O, Perianayagam MC, Vaidya VS et al. Urinary N-acetyl-beta- (D) – glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007 Mar;18 (3):904–12.
  27. Damman K, van Veldhuisen DJ, Navis G et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart. 2010 Aug;96 (16):1297–302.
  28. Jungbauer CG, Birner C, Jung B et al. Kidney injury molecule-1 and N-acetyl-β-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail. 2011 Oct;13 (10):1104–10.
  29. Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur Heart J. 2011 Nov;32 (21):2705–12.
  30. Damman K, Masson S, Hillege HL et al. Tubular damage and worse­ning renal function in chronic heart failure. JACC Heart Fail. 2013 Oct;1 (5):417–24.
  31. Кузьмин О. Б., Белянин В. В., Жежа В. В. Легкая дисфункция почек у больных сердечной недостаточностью: доклинические признаки и их прогностическое значение. Журнал Сердечная Недостаточность. 2014;15 (2):126–31.
Кузьмин О. Б., Белянин В. В., Жежа В. В. и др. Диагностическая и прогностическая ценность новых биомаркеров повреждения почек у больных острой и хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2015;16 (1):57–64

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En